About Viamet Pharmaceuticals
Viamet Pharmaceuticals is a Healthcare company based in Durham (United States) founded in 2005 by Thomas OHalloran, and was acquired by NovaQuest Capital Management in January 2018. Therapies for chronic fungal infections are developed using metalloenzyme inhibitors. Viamet Pharmaceuticals has raised $160.8 million across 9 funding rounds from investors including Woodford Investment Management, U.S. Department of Defense and Brandon Point Industries. The company has 22 employees. The company was acqui-hired. Viamet Pharmaceuticals offers products and services including Aivala.com, DevelopUniversity.com, Billionaires.University, FireProtectionConsultant.com, and Fescousa.com. Its focus areas include Life Sciences, Infectious Diseases, Drugs and Fungal. Its legal entity is MYCOVIA PHARMACEUTICALS (NC), INC. Its competitors include Scynexis, Amplyx Pharmaceuticals and Elion Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Viamet Pharmaceuticals was founded in 2005 in Durham, United States, within the biotechnology sector. Small molecule inhibitors of metalloenzymes are identified through the Metallophile platform to address chronic and life-threatening fungal infections. The lead candidate, VT-1161, is advanced in Phase 2b trials for recurrent vulvovaginal candidiasis and onychomycosis. Preclinical efforts include VT-1129 for cryptococcal meningitis and VT-1598 for invasive fungal infections.
- Headquarters Durham, United States
- Employees 22
- Founders Thomas OHalloran
- Stage Acquired
- SectorsHealthcare
- Website viamet.com
- Social LinkedIn
- Acquired by NovaQuest Capital Management (Jan 2018)
- Legal Name Mycovia Pharmaceuticals (Nc), Inc.
- Total Equity Funding$160.8M (USD)
in 9 rounds
- Latest Funding Round$12M (USD), Series E
Sep 2016
- InvestorsWoodford Investment Management
& 8 more
- Employee Count22
- Acquired byNovaQuest Capital Management
(Jan 2018)
Products & Services of Viamet Pharmaceuticals
Viamet Pharmaceuticals offers a comprehensive portfolio of products and services, including Aivala.com, DevelopUniversity.com, Billionaires.University, FireProtectionConsultant.com, and Fescousa.com.
Offers AI training to empower healthcare professionals for work and profit.
Provides online courses for skill development and education.
Delivers strategies for wealth-building and business acumen.
Offers fire safety consulting and training solutions.
Provides leading fire protection and emergency services.
Manages lodging and logistics for nuclear energy operations.
Advances satellite networks for global communications.
Delivers AI-driven content creation and copying tools.
Offers AI resources for enhancing business skills.
Funding Insights of Viamet Pharmaceuticals
Viamet Pharmaceuticals has successfully raised a total of $160.8M across 9 strategic funding rounds. The most recent funding activity was a Series E round of $12 million completed in September 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $160.8M
- Total Rounds 9
- Last Round Series E — $12M
- First Round $200,000
(Aug 2005)
- Investors Count 8
All 9 funding rounds of Viamet Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2016 | $12M | Series E | – | – | – |
| Jun 2015 | $1.95M | Grant | – | – | |
| Oct 2014 | $60M | Series D | – | – | |
| Feb 2014 | $10M | Series C | – | – | – |
| Oct 2012 | $10M | Series C | – | – | – |
| Dec 2011 | $39.6M | Series C | – | – | – |
| Feb 2011 | $25M | Series B | – | – | |
| Jun 2007 | $4M | Series A | – | – | |
| Aug 2005 | $200,000 | Seed | – | – |
9 investors in total: 9 institutional.
Investors in Viamet Pharmaceuticals
Viamet Pharmaceuticals has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include Woodford Investment Management, U.S. Department of Defense and Brandon Point Industries.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| brandonpti.com | ||||
Investments are made in innovative life science companies globally. | nvfund.com | Basel, Switzerland | ||
Early-stage life sciences investments are targeted in the healthcare sector. | lillyventures.com | Indianapolis, United States | ||
Tech & Life Sciences focused VC firm investing in early stage companies in the US & Europe | hatterasvp.com | Durham, United States | ||
Early-stage life sciences and tech focused VC firm funding companies in the US | intersouth.com | Durham, United States | ||
| astellasventure.com | ||||
PE firm focused on life science and healthcare companies | novaquest.com | Raleigh, United States | ||
Military forces are provided by the U.S. Department of Defense for national security. | defense.gov | Washington, D.C., United States | ||
Diversified investment portfolios are managed for clients by the firm. | 2014 | woodfordfunds.com | Swindon, United Kingdom |
Investor details for Viamet Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Viamet Pharmaceuticals
1 people are tracked at Viamet Pharmaceuticals (1 in leadership); the tracked headcount is 22.
| Name | Role | Group |
|---|---|---|
Thomas OHalloran | Co-Founder | Leadership |
Complete people profiles for Viamet Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Viamet Pharmaceuticals
4 dated milestones of Viamet Pharmaceuticals across 13 years, from founding to its latest funding, stage changes and deals.
- Founded Viamet Pharmaceuticals is founded.
- Funding First funding round of $200K.
- Funding Latest funding round, Series E, of $12.0M.
- Exit Acquired by NovaQuest Capital Management.
Competitors of Viamet Pharmaceuticals
Viamet Pharmaceuticals has 3 listed competitors in our database, 3 of them funded. They include Scynexis, Amplyx Pharmaceuticals and Elion Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| scynexis.com | 1999 | Jersey, United States | $62.65M | 50 | Developing glucan synthase inhibitors for the treatment of fungal infections. | |
| amplyx.com | 2006 | San Diego, United States | $144.31M | 15 | Broad-spectrum fungal enzyme inhibitors are developed by clinical-stage biopharma. | |
| eliontx.com | 2024 | New York, United States | $81M | Therapeutics for invasive fungal infections are developed by Elion Therapeutics. |
Detailed competitors of Viamet Pharmaceuticals
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Infectious Diseases
3 companies that operate in the same segment as Viamet Pharmaceuticals (Infectious Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 | |
Therapeutics for drug-resistant bacterial infections are developed. | 2013 | Cambridge, Massachusetts, United States | USD 114.7 M | USD 59.62 M | 32 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Viamet Pharmaceuticals
Complete news archive for Viamet Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Viamet Pharmaceuticals
Viamet Pharmaceuticals was founded in 2005.
Viamet Pharmaceuticals is headquartered in Durham, United States. It is registered at Durham, North Carolina, United States.
Viamet Pharmaceuticals is a funded company, having raised a total of $160.8M across 9 funding rounds to date. The company's 1st funding round was a Seed of $200K, raised on Aug 2005.
Viamet Pharmaceuticals has 22 employees.
Viamet Pharmaceuticals was founded in 2005 in Durham, United States, within the biotechnology sector. Small molecule inhibitors of metalloenzymes are identified through the Metallophile platform to address chronic and life-threatening fungal infections. The lead candidate, VT-1161, is advanced in Phase 2b trials for recurrent vulvovaginal candidiasis and onychomycosis. Preclinical efforts include VT-1129 for cryptococcal meningitis and VT-1598 for invasive fungal infections.
Viamet Pharmaceuticals's top competitors include Scynexis, Amplyx Pharmaceuticals and Elion Therapeutics.
Viamet Pharmaceuticals offers Aivala.com, DevelopUniversity.com, Billionaires.University, FireProtectionConsultant.com, and 5 more products and services.
Viamet Pharmaceuticals has 9 investors. Key investors include Woodford Investment Management, U.S. Department of Defense, Brandon Point Industries, Novartis Venture Fund, and Lilly Ventures.
Viamet Pharmaceuticals operates through Mycovia Pharmaceuticals (Nc), Inc..
Yes. Viamet Pharmaceuticals was acquired by NovaQuest Capital Management in January 2018.